论文部分内容阅读
目的研究胰岛素增敏剂治疗多囊卵巢综合征内分泌紊乱的临床疗效。方法 120例多卵巢综合征患者,随机分为实验组和对照组,各60例。对照组患者采取常规治疗,实验组在对照组治疗基础上增加二甲双胍进行综合治疗。治疗6个月后,比较两组患者胰岛素抵抗指数,空腹及餐后3h胰岛素、血糖水平,雌二醇和体质量指数(BMI)。结果两组患者各时间点血糖水平比较差异无统计学意义(P>0.05);实验组患者胰岛素水平均低于对照组,差异具有统计学意义(P<0.05)。实验组胰岛素抵抗指数为为(3.22±1.26)、雌二醇为(120.3±19.5)U/L、BMI为(20.7±1.5)kg/m~2优于对照组的(5.64±2.95)、(134.6±20.5)U/L,(27.6±3.2)kg/m~2,差异具有统计学意义(P<0.05)。结论在多卵巢综合征的内分泌紊乱治疗中,胰岛素增敏剂能增强胰岛素敏感性,提高治疗效果,具有较好的临床推广价值。
Objective To study the clinical efficacy of insulin sensitizer in the treatment of endocrine disorders of polycystic ovary syndrome. Methods 120 patients with multiple ovarian syndrome were randomly divided into experimental group and control group, 60 cases in each. Control group of patients taking conventional treatment, experimental group in the control group based on the increase of metformin comprehensive treatment. After 6 months of treatment, the insulin resistance index, 3h fasting and postprandial insulin, blood glucose, estradiol and body mass index (BMI) were compared between the two groups. Results There was no significant difference in blood glucose level between the two groups at each time point (P> 0.05). The insulin level in the experimental group was lower than that in the control group (P <0.05). The insulin resistance index of experimental group was (3.22 ± 1.26), that of estradiol was (120.3 ± 19.5) U / L and that of BMI was (20.7 ± 1.5) kg / m ~ 2 was 5.64 ± 2.95, 134.6 ± 20.5) U / L and (27.6 ± 3.2) kg / m ~ 2, respectively. The difference was statistically significant (P <0.05). Conclusion In the treatment of endocrine disorders of polycystic ovary syndrome, insulin sensitizers can enhance insulin sensitivity, improve the therapeutic effect, and have a good clinical value.